UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 486

Sortiert nach

Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2556-2568

2005

Volltextzugriff (PDF)

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

PLoS medicine, 2005-03, Vol.2 (3), p.e73-e73

2005

Volltextzugriff (PDF)

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5892-5899

2005

Volltextzugriff (PDF)

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

PLoS medicine, 2005-01, Vol.2 (1), p.e17-e17

2005

Volltextzugriff (PDF)

Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

Clinical cancer research, 2006-02, Vol.12 (3), p.839-844

2006

Volltextzugriff (PDF)

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5900-5909

2005

Volltextzugriff (PDF)

Regulation of fibrinolysis by S100A10 in vivo

Blood, 2011-09, Vol.118 (11), p.3172-3181

2011

Volltextzugriff (PDF)

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2004-03, Vol.22 (6), p.1103-1109

2004

Volltextzugriff (PDF)

CO124 Indirect Comparison of Efficacy and Safety for Aumolertinib vs Osimertinib in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Value in health, 2022-12, Vol.25 (12), p.S42-S42

2022

Volltextzugriff (PDF)

Abstract P6-07-04: Comprehensive genomic profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-07-04

2017

Volltextzugriff (PDF)

Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase

Clinical cancer research, 2000-12, Vol.6 (12), p.4885-4892

2000

Volltextzugriff (PDF)

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

Cancer, 2005-06, Vol.103 (11), p.2344-2348

2005

Volltextzugriff (PDF)

Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas

Journal of clinical oncology, 2006-04, Vol.24 (11), p.1700-1704

2006

Volltextzugriff (PDF)

Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib

Journal of clinical oncology, 2005-01, Vol.23 (1), p.165-174

2005

Volltextzugriff (PDF)

Abstract PD3-05: Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD3-05-PD3-05

2019

Volltextzugriff (PDF)

Abstract P3-06-18: Comprehensive genomic profiling of carcinosarcomas of the breast

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-06-18

2019

Volltextzugriff (PDF)

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein : A phase II clinical trial

Cancer, 2005-05, Vol.103 (10), p.2128-2131

2005

Volltextzugriff (PDF)

A pilot study of observed physician-parent-child communication and child satisfaction in a gastroenterology clinic

Patient preference and adherence, 2018-01, Vol.12, p.1327-1335

2018

Volltextzugriff (PDF)

Abstract P2-12-01: Comprehensive genomic profiling of 34 cases of breast angiosarcoma

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-12-01

2017

Volltextzugriff (PDF)

Abstract P1-05-08: Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-05-08

2017

Volltextzugriff (PDF)

Abstract P1-05-07: Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of NF1 and other genes associated with PI3K and RAS pathway activation

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-05-07

2017

Volltextzugriff (PDF)

Abstract P2-09-15: NTRK fusions in breast cancer: Clinical, pathologic and genomic findings

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-09-15

2018

Volltextzugriff (PDF)

Abstract PD8-01: CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas differ in genomic signatures and opportunities for targeted and immunotherapies

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD8-01-PD8-01

2018

Volltextzugriff (PDF)

Cystic fibrosis: addressing the transition from pediatric to adult-oriented health care

Patient preference and adherence, 2013-12, Vol.7 (default), p.1221-1226

2013

Volltextzugriff (PDF)

Drug development in the MD Anderson Cancer Center (MDACC) Clinical Translational Research Center (CTRC) – 2011–2015: The challenge of precision medicine in a very broad playing field

European journal of cancer (1990), 2016-12, Vol.69, p.S138-S139

2016

Volltextzugriff (PDF)

1 – 25 von 486

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(433)
Mit Volltextzugriff
(411)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(486)
Japanisch
(57)
Deutsch
(1)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(390)
Life Sciences & Biomedicine
(268)
Humans
(189)
Biological And Medical Sciences
(121)
Male
(118)
Physical Sciences
(117)
Female
(111)
Medical Sciences
(96)
Physics
(75)
Animals
(70)
Adult
(66)
Middle Aged
(66)
Oncology
(63)
Aged
(50)
Technology
(39)
Lung Neoplasms - Drug Therapy
(35)
Pharmacology. Drug Treatments
(35)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(30)
Fundamental And Applied Biological Sciences. Psychology
(27)
Physics, Particles & Fields
(27)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

Regulation of fibrinolysis by S100A10 in vivo

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

CO124 Indirect Comparison of Efficacy and Safety for Aumolertinib vs Osimertinib in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Abstract P6-07-04: Comprehensive genomic profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy

Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas

Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib

Abstract PD3-05: Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth

Abstract P3-06-18: Comprehensive genomic profiling of carcinosarcomas of the breast

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein : A phase II clinical trial

A pilot study of observed physician-parent-child communication and child satisfaction in a gastroenterology clinic

Abstract P2-12-01: Comprehensive genomic profiling of 34 cases of breast angiosarcoma

Abstract P1-05-08: Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression

Abstract P1-05-07: Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of NF1 and other genes associated with PI3K and RAS pathway activation

Abstract P2-09-15: NTRK fusions in breast cancer: Clinical, pathologic and genomic findings

Abstract PD8-01: CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas differ in genomic signatures and opportunities for targeted and immunotherapies

Cystic fibrosis: addressing the transition from pediatric to adult-oriented health care

Drug development in the MD Anderson Cancer Center (MDACC) Clinical Translational Research Center (CTRC) – 2011–2015: The challenge of precision medicine in a very broad playing field

Suchergebnisse filtern